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Excess of glucocorticoids (GC) is a leading cause of bone fragility, and novel therapeutic targets 
are sorely needed. We report that genetic deletion or pharmacological inhibition of proline-rich 
tyrosine kinase 2 (Pyk2) prevents GC-induced bone loss, by overriding GC effects of 
detachment-induced bone cell apoptosis (anoikis). In wild type (WT) or vehicle-treated mice, GC 
either prevented osteoclast apoptosis or promoted osteoblast/osteocyte apoptosis. In contrast, 
mice lacking Pyk2 (KO) or treated with Pyk2 kinase inhibitor PF-431396 (PF) were protected. 
KO or PF-treated mice were also protected from GC-induced bone resorption, microarchitecture 
deterioration, and weakening of biomechanical properties. In KO and PF-treated mice, GC 
increased osteoclasts in bone and circulating TRAP5b, an index of osteoclast number. However, 
bone surfaces covered by osteoclasts and circulating CTX, an index of osteoclast function, were 
not increased. The mismatch between osteoclast number vs function induced by Pyk2 
deficiency/inhibition was due to osteoclast detachment and anoikis. Further, GC prolongation of 
osteoclast lifespan was absent in KO and PF-treated osteoclasts, demonstrating Pyk2 as an 
intrinsic osteoclast-survival regulator. Circumventing Pyk2 activation preserves skeletal integrity 
by preventing GC effects on bone cell survival (pro-apoptotic for osteoblasts/osteocytes, anti-
apoptotic for osteoclasts) and GC-induced bone resorption. Thus, Pyk2/anoikis signaling as a 
new therapeutic target for GC-induced osteoporosis.  
Introduction 
Glucocorticoids (GC), produced and released by the adrenal glands, regulate numerous 
physiological processes in a wide range of tissues (1;2). Because of their profound 
immunosuppressive and anti-inflammatory actions, these agents are widely prescribed to treat an 
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extensive array of pathological conditions, including rheumatoid arthritis, asthma, inflammatory 
bowel disease, chronic lung, liver and skin diseases, as well as for the management of organ 
transplantation and as components of chemotherapy regimens for cancers (3). However, 
pharmacological administration of GC, similar to pathologic endogenous elevation, is associated 
with severe adverse side effects manifested in several tissues and organs, in particular the 
skeleton (4). Prolonged GC administration leads to a prominent loss of bone mass and strength 
and increased risk for atraumatic fractures in approximately 30-50% of patients (4;5). The initial 
rapid bone loss induced by GC is due to exaggerated bone resorption and is accompanied by 
suppressed bone formation. Excess GC also causes muscle weakness with the consequent loss of 
body balance and increased propensity to fall, which contribute to the risk of bone fractures (6-
8).  
The current standard of care, bisphosphonates (4), as well as the anti-RANKL antibody 
recently approved by the FDA to treat GC-induced osteoporosis (9), effectively prevent bone 
loss by inhibiting resorption. However, these agents lead to further reduction in bone formation 
compared to GC alone, thus preventing rebuilding the bone that was lost (10-12). In addition, 
profound reduction in bone turnover is not desirable since it leads to accumulation of 
microdamage and advanced glycation endproducts, which are associated with osteonecrosis of 
the jaw with long-term treatments (13;14). Severe suppression of bone turnover can also reduce 
toughness, the energy that bone tissue absorbs before failure, with potential increased risk of 
low-energy atypical fractures (13). Thus, there is an unmet need for therapeutic interventions that 
prevent GC-induced bone disease that lack these skeletal complications.  
Deterioration of bone tissue is due to direct effects of GC on bone cells (15;16). Rapid 
increased bone resorption is caused by accumulation of osteoclasts on bone surfaces, resulting 
from stimulation of osteoclast generation combined with prolongation of the lifespan of 
preexisting osteoclasts (17). In addition, GC drastically inhibit bone formation, by suppressing 
the synthetic capacity of osteoblasts (inhibiting osteocalcin and collagen 1 synthesis and 
stimulating Wnt antagonist production) and by promoting osteoblast and osteocyte apoptosis 
(18). A remarkable feature of GC effects on bone is the opposing regulation of apoptosis 
depending on the bone cell lineage, i.e. anti-apoptotic for osteoclasts and pro-apoptotic for 
osteoblasts/osteocytes. However, the underlying mechanism of this hallmark have remained 
elusive.  
All osteoclasts die by apoptosis upon completing resorption (19). Failure to timely undergo 
apoptosis is associated with increased depth of resorption pits, which leads to cortical and 
trabecular bone thinning, and to trabeculae perforation and loss of connectivity in cancellous 
bone (20). Most osteoblasts (~70% in human bone) also undergo apoptosis after producing bone 
matrix proteins; and osteocytes, although long-lived cells, can prematurely apoptose due to 
changes in hormonal as well as mechanical cues (21). The survival of bone cells is critically 
dependent of their attachment to the surrounding bone matrix through integrins. Signaling 
mediated by integrins is bidirectional. Extracellular matrix proteins bind to integrins and activate 
intracellular pathways, referred to as “outside-in” signaling. In turn, activation of intracellular 
pathways alter the interaction of integrins with the surrounding matrix, referred to as “inside-out” 
signaling. Disrupted interactions between integrins and the extracellular matrix leads to 
detachment and apoptosis (termed anoikis, the Greek word for homelessness) of both osteoclasts 
and osteoblastic cells (22;23). In particular, GC activate in cultured osteocytic cells the proline-
rich tyrosine kinase 2 (Pyk2), a member of the focal adhesion kinase (FAK) family of 
nonreceptor tyrosine kinases, which in turn induces osteocytic cell detachment and anoikis (23). 
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However, whether this pathway is involved in the opposing effects of GC on osteoblast/osteocyte 
vs osteoclast apoptosis in vivo had remained unknown.  
We report herein that Pyk2 is an essential mediator of anoikis regulated by GC in vivo in 
bone cells of both lineages: osteoclasts and osteocytes/osteoblasts. Pyk2 activation is required for 
GC-induced prolongation of osteoclast lifespan and, conversely, for promotion of osteoblast and 
osteocyte apoptosis. Moreover, circumventing Pyk2 activation by genetic or pharmacological 
means prevents GC-induced bone loss and increased skeletal fragility, by stimulating anoikis of 
osteoclasts while preventing anoikis of osteoblasts and osteocytes. Furthermore, overriding GC 
effects on bone cell survival by Pyk2 inhibition is achieved without altering bone renewal rate or 
bone biomechanical material properties. Hence, targeting the Pyk2/anoikis pathway represents a 
novel mechanistic approach to preserve skeletal integrity with GC excess, devoid of undesirable 
skeletal complications.  
Materials and methods  
Mice and tissue procurement.  
Skeletally mature four-month old female mice with global deletion of Pyk2 (KO) and wild type 
littermate controls (WT) of C57BL/6 background were generated from breeders provided by Dr. 
Charles Turner, Indiana University, originally described in Okigaki et al. 2003 (24). Genotyping 
was performed by extracting genomic DNA from tissue samples, followed by  PCR reaction 
using the following primers Pyk2 reverse (CCTGCTGGCAGCCTAACCACAT), Pyk2 wild type 
forward (GGAGGTCTATGAAGGTGTCTACACGAAC), and Pyk2 mutated forward 
(GCCAGCTCATTCCTCCCACTCAT). PCR products were run on an agarose gel with 
electrophoresis to distinguish the wild type and Pyk2 KO bands. Mice (5 per cage) were fed with 
a regular diet (Teklad Global 18% Protein Extruded Rodent Diet Sterilizable, Catalog number 
2018SX, Harlan/ENVIGO, Indianapolis, IN, USA), received water ad libitum, and were 
maintained on a 12-h light/dark cycle in polycarbonate cages at the Laboratory Animal Research 
Center (LARC), at Indiana University School of Medicine. Mice were implanted with slow-
release pellets delivering placebo, 1.4 mg/kg/d (GC1), or 2.1 mg/kg/d (GC2) prednisolone 
(Innovative Research of America, Sarasota, FL, USA) for four weeks (25). Previous studies 
showed that these doses reproduce in the mouse the hallmarks of GC‐induced osteoporosis and 
are equivalent to medium and high therapeutic glucocorticoid doses in humans (25;26). C57BL/6 
four-month old female mice were injected with vehicle or 10 mg/kg of the Pyk2/FAK inhibitor 
PF-431396 (PF) (Tocris Bioscience, Bristol, UK) five times per week, as previously published 
(27), beginning three days prior to placebo or GC2 pellet implantation for two weeks. To 
measure the dynamic histomorphometric indexes mineralizing surface to bone surface (MS/BS), 
mineral apposition rate (MAR), and bone formation rate normalized to bone surface (BFR/BS), 
KO and WT mice were injected 10 and 3 days prior to sacrifice with calcein (30 mg/kg, Sigma-
Aldrich, St. Louis, MO, USA) and alizarin red (50 mg/kg, Sigma-Aldrich, St. Louis, MO, USA) 
solutions, respectively. The use of two different colors of fluorochromes permits the unequivocal 
identification of first and second labels and increases accuracy in the measurement of the 
distance between the two labels required for MAR calculation. Mice were euthanized by first 
sedation with 2% isoflurane (Abbott Laboratories, Chicago, IL, USA) administered by a Drager 
19.1 Anesthetic Vaporizer, and then followed by cervical dislocation. Bones were dissected and 
processed as indicated below, and muscles were also dissected and weighed. Analysis was 
performed in a blinded fashion. All animal procedures were approved by the Institutional Animal 
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Care and Use Committee (IACUC) of Indiana University School of Medicine, and animal care 
was carried out in accordance with institutional guidelines.  
BMD measurement and micro-CT analysis.  
Lean body mass and BMD of the total body excluding the head and the tail, the lumbar spine 
(L1-L6), and the femur were measured by dual energy X-ray absorptiometry (DXA) scanning by 
using a PIXImus II densitometer (GE Medical Systems, Lunar Division, Madison, WI, USA). 
DXA measurements were performed 2-4 days before (initial) and 14 or 28 days (final) after 
pellet implantation (25;28). Mice were randomized to the experimental groups based on initial 
spine BMD. Briefly, mice were sorted by spinal BMD starting from the highest BMD, and then 
randomly distributed to the treatment groups. After randomization, no statistical differences on 
spinal BMD were found between experimental groups.  
For micro-CT analysis, L6 vertebral and femoral bones were cleaned of soft tissue, fixed in 10% 
buffered formalin, and stored in 70% ethanol until scanned.  Vertebrae were scanned at 6-µm 
resolution (Skyscan 1172, SkyScan, Aartselaar, Belgium) and femoral bones were scanned at 10-
µm resolution (SCANCO 35, SCANCO Medical, Brüttisellen, Switzerland) and cancellous bone 
measurements were done 60 µm away from the growth plates as previously described (29). 
Cortical bone of the midshaft femur was performed for a 0.2 mm region located at the calculated 
femoral midpoint. The nomenclature for micro-CT indexes follows the guidelines previously 
recommended (30).   
Mechanical testing.  
The mechanical properties of L6 vertebrae were determined by axial compression after removal 
of vertebral processes and the cranial and caudal endplates. Vertebral bodies were loaded at a 
rate of 0.5 mm/min until failure (100P225 Modular Test Machine, TestResources, Shakopee, 
MN, USA), as previously described (25). The mechanical properties of femoral mid-diaphysis 
were assessed by three-point bending using standard methods (31). Femurs were placed with the 
posterior side down upon the bottom support (9 mm wide) with the descending probe contacted 
with the central anterior surface and loaded at a rate of 2 mm/min until failure (100P225 Modular 
Test Machine, TestResources, Shakopee, MN, USA), as previously described (32). Structural or 
extrinsic properties (energy to ultimate force, ultimate force, and stiffness) of the vertebra or 
femur were derived from the load/displacement curves obtained during the vertebral 
compression or three-point bending tests, respectively. The material or intrinsic properties 
(toughness, ultimate stress, and Young’s modulus or intrinsic stiffness) were derived from the 
structural properties, by taking into account the geometry and volume of the samples quantified 
by micro-CT, following the calculations previously published (31;33). 
Apoptosis analysis.  
Apoptosis of osteoblasts and osteocytes was detected by the transferase-mediated biotin-dUTP 
nick end-labeling (TUNEL) reaction (GeneCopoeia, Rockville, MD, USA) in undecalcified 
vertebral and femoral bone sections counterstained with 2% methyl green as previously 
described (34). Apoptosis of osteoclasts and marrow osteoclasts was detected in double stained 
TRAPase, to identify osteoclasts, and TUNEL, to identify apoptotic cells, in the cancellous bone 
region starting 300µm from the distal growth plate and ending 1100µm proximal to the distal 
growth plate of paraffin-embedded femora. The total number of TRAPase positive cells (TRAP 
+cells) was also quantified including multinucleated cells both on bone surfaces and in the 
marrow as well as TUNEL positive and negative, which was then normalized by both bone 
surface and marrow area. The number of live and TUNEL positive marrow osteoclasts was 
AD
VA
N
CE
 A
RT
IC
LE
:
En
d
o
cr
in
o
lo
g
y
D
ow
nloaded from
 https://academ
ic.oup.com
/endo/advance-article-abstract/doi/10.1210/en.2019-00237/5487989 by IU
PU
I U
niversity Library user on 24 June 2019
AD
VA
NC
E 
AR
TI
CL
E
Endocrinology; Copyright 2019  DOI: 10.1210/en.2019-00237 
 
 
5
normalized to the total marrow area. The prevalence of apoptotic osteoblasts, osteocytes, 
osteoclasts, and marrow osteoclasts was calculated by enumerating the total number and TUNEL 
positive cells exhibiting condense chromatin, nuclear fragmentation, or cell shrinkage.    
Serum biochemistry.  
Blood was collected 2 and 4 weeks after pellet implantation from the facial vein of 3-hour fasted 
mice. N-terminal propeptide of type I procollagen (P1NP) (35), C-terminal telopeptides of type I 
collagen (CTX) (36), and tartrate-resistant acid phosphatase form 5b (TRAP5b) (37) were 
measured using enzyme-linked immunosorbent assays (Immunodiagnostic Systems Inc., 
Gaithersburg, MD, USA) (25;28). Osteocalcin (OCN) (38) was measured using the Mouse 
Osteocalcin KIA Kit (Alfa Aesar, Tewksbury, MA, USA).   
Bone histomorphometry.  
A subset of 3-6 samples was studied. L1-3
 
vertebrae and femoral bones were fixed in 10% 
neutral buffered formalin and embedded undecalcified in methyl methacrylate as previously 
described (34). Dynamic histomorphometry measurements were performed 4-µm unstained bone 
sections under epifluorescence microscopy. Histomorphometric analysis was performed using 
OsteoMeasure High Resolution Digital Video System (OsteoMetrics, Decatur, GA, USA) 
interfaced to an Olympus BX51 fluorescence microscope (Olympus America Inc., Center Valley, 
PA, USA) (28). Osteoclasts were quantified on L2 lumbar vertebral by analyzing the whole 
vertebral body region and distal femoral by analyzing the femoral cancellous bone region 
(starting 300µm from the distal growth plate and ending 1100µm proximal to the distal growth 
plate) of thin sections stained for tartrate-resistant acid phosphatase (TRAPase) and 
counterstained with Toluidine Blue, as previously published (25;28). Osteoclasts were defined as 
TRAPase positive cells attached to bone with 2 or more nuclei, following standardized 
histomorphometry guidelines by the American Society for Bone and Mineral Research (39) and 
recent publications (40-42). Osteoclast number was calculated by dividing the total number of 
osteoclasts attached to bone surfaces by the total bone surface (number/mm); and osteoclast 
surface was calculated by dividing the bone surface covered by osteoclasts by total bone surface, 
and multiplied by 100 (in %). A marrow osteoclast was defined as a multinucleated TRAPase 
positive cell with 2 or more nuclei separated from the bone surface by at least one other cell. 
Marrow osteoclast number was calculated by dividing the total number of marrow osteoclasts by 
the marrow area (number/mm2). Longitudinal sections of the distal femurs were stained for von 
Kossa and counterstained with McNeal, as previously described (28).  
Quantitative PCR.  
Total RNA was extracted from vertebral lumbar bones (L4) and quantitative PCR was performed 
as previously described (25). RNA was extracted with TRIzol (Invitrogen, Carlsbad, CA, USA), 
and cDNA was synthesized by using high capacity cDNA reverse transcription kit (Applied 
Biosystems Inc., Foster City, CA, USA). Primer and probe sets were from Applied Biosystems 
or from Roche Applied Science (Indianapolis, IN, USA). Relative mRNA expression was 
normalized to the housekeeping gene ribosomal protein, large P2 (Rplp2) using the ∆Ct method. 
Ratios between genes of interest and housekeeping gene are expressed as fold change compared 
to WT mice receiving placebo.  
  Mineralization assay.  
Primary osteoblastic cells were isolated from the neonatal calvarial bones of C57BL/6 mice, KO, 
or WT littermate control mice, and plated at 5,000 cells/cm2 density in MEM Alpha medium 
with 10% fetal bovine serum and 1% penicillin/streptomycin as previously described (25;43). 
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Osteogenic medium was used after cultures reached confluence consisting of 50 µg/ml ascorbic 
acid and 10 mM β-glycerophosphate and treated with 1µM dexamethasone or the corresponding 
vehicle (ethanol), and Pyk2 inhibitor (PF-431396) or the corresponding vehicle (DMSO). 
Medium was replaced every 2-3 days, and mineralization was visualized using the OsteoImage 
Mineralization Assay Kit (Lonza Walkersville Inc., Walkersville, MD, USA) or Alizarin Red S 
(Sigma-Aldrich, St. Louis, MO, USA) staining (43). Mineralization was quantified using a 
microplate reader for Lonza staining (492/520 nm excitation/emission fluorescence) or for 
Alizarin Red S staining (405 nm absorbance) (25;43).     
Osteoclast apoptosis assay in vitro.  
Bone marrow cells were flushed with sterile PBS from tibiae and femora of C57BL/6 mice or 
WT and KO mice and cultured in MEM Alpha medium with 10% fetal bovine serum and 1% 
penicillin/streptomycin for 48 hours, as previously described (17). Non-adherent cells were 
collected, re-plated at 300,000 cells/cm2 density and differentiated with 80 ng/ml recombinant 
murine soluble RANKL (PeproTech, Rocky Hill, NJ, USA) and 20 ng/ml recombinant murine 
M-CSF (PeproTech, Rocky Hill, NJ, USA) for 4-6 days. Medium was replaced every 2 days and 
cells were treated with 10-5M alendronate or corresponding vehicle (PBS) one hour prior to 1µM 
dexamethasone or the corresponding vehicle (EtOH) addition. After 24 hours, cells were fixed 
with 10% buffered formalin, rinsed with dH2O, and stained for TRAPase (Sigma-Aldrich, St. 
Louis, MO, USA) with hematoxylin counterstaining. Apoptotic osteoclasts were identified by the 
presence of morphologic characteristics such as the loss of cell membrane integrity, nuclear 
condensation, and fragmentation. 
Statistical analysis.  
Data are expressed as means ± standard deviations (SD). Sample differences were evaluated 
using SigmaPlot 12.0 (Systat Software, Inc., San Jose, CA, USA). Statistically identified outliers 
for particular end points (value ± 2 times SD from the mean) were removed. Data of the in vivo 
and in vitro experiments were analyzed by two-way ANOVA using genotype (WT vs KO) or 
intervention (vehicle vs PF-431396) and treatment (placebo vs glucocorticoid) as independent 
variables. For apoptotic osteoclasts in vitro assays, a three-way ANOVA was used for genotype 
(WT vs KO) or intervention (vehicle vs PF-431396), treatment (vehicle vs dexamethasone), and 
apoptotic agent (vehicle vs alendronate). When ANOVA detected a significant interaction 
between the variables or a significant main effect, the post-hoc test Tukey was used to determine 
the significance of the effect of the treatment within each genotype or intervention condition.  
Study approval.  
All animal procedures were approved by the Institutional Animal Care and Use Committee of 
Indiana University School of Medicine, and animal care was carried out in accordance with 
institutional guidelines. 
Results 
Genetic deletion of Pyk2 protects from GC-induced loss of bone mass and strength, and 
osteoblast/osteocyte apoptosis, but not from the suppression of bone formation.  
Mice lacking Pyk2 (KO) display higher bone mass at all sites, measured by DXA (Figure 1A); 
and increased vertebral (L6) cancellous bone (BV/TV), trabecular thickness (Tb.Th), trabecular 
number (Tb.N), and decreased trabecular separation (Tb.Sp), quantified by micro-CT (Figure 
1B-C), consistent with previous reports (27;44). In WT mice, administration of two different 
doses of the GC prednisolone (GC1=1.4 or GC2=2.1 mg/kg/d) decreased total, spine, and femur 
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BMD (Figure 1A) and trabecular thickness (Figure 1B-C). The higher GC dose also decreased 
cancellous BV/TV in WT mice (Figure 1C, left graph). In contrast, KO mice were resistant to 
GC effects on bone mass and volume (Figure 1A-C). WT and KO littermate mice exhibit similar 
body weight that was not altered by GC (not shown), and similar lean body mass that was 
reduced by GC similarly in both genotypes (Figure 2A). In addition, the weight of tibialis 
anterior and gastrocnemius muscles was decreased by GC to a similar extent in WT and KO 
mice (Figure 2B).  
KO mice also exhibited enhanced structural (or extrinsic) mechanical properties of ultimate 
force, energy to ultimate load, and stiffness, measured in vertebral bone compared to WT mice 
(Table 1). However, no differences in material (or intrinsic) mechanical properties (toughness, 
ultimate stress, and Young’s modulus) were detected between the two genotypes. These findings 
suggest that the gain in bone strength in KO mice is due to increased bone mass and not to 
alterations at the tissue level (i.e. mineralization or collagen structure). GC treatment decreased 
the structural properties of ultimate force and energy to ultimate load, as well as the material 
property of toughness in WT mice (Figure 1D). In contrast, KO mice were protected from any 
changes in structural or material mechanical properties induced by GC.   
We next examined the underlying mechanism of the protection from GC-induced bone loss 
by Pyk2 deletion. Overall, deletion of Pyk2 under basal conditions did not alter osteoblast or 
osteocyte apoptosis, circulating levels of formation and remodeling markers (P1NP or OCN, 
respectively), or dynamic histomorphometric parameters (MS/BS, MAR, and BFR/BS), except 
for a decrease in P1NP exhibited by KO mice detected at 4 weeks but not at 2 weeks after pellet 
implantation (Figure 1E-H). GC induced the expected increase in osteoblast and osteocyte 
apoptosis in cancellous and cortical bone in WT mice, whereas KO mice were protected (Figure 
1E). This finding is consistent with the previous demonstration that Pyk2 kinase expression and 
activity is required for GC-induced apoptosis of osteocytic cells in vitro (23). However, KO mice 
were not protected from the reduction of bone formation induced by GC. Thus, GC decreased 
serum P1NP and OCN in both WT and KO mice (Figure 1F-G); and decreased MS/BS, MAR, 
and BFR/BS to the same extent in WT and KO mice (Figure 1H). GC reduced the mRNA 
expression of osteocalcin, collagen 1a1, and alkaline phosphatase in bones from both WT and 
Pyk2 KO mice (Figure 1I). This persistent inhibitory effect of GC on the biosynthetic activity of 
osteoblasts in the KO mice explains the inability of Pyk2 inhibition to prevent the decreased 
bone formation induced by the hormones.         
Short-term pharmacologic Pyk2 inhibition prevents GC-induced bone loss, fragility, and 
osteoblast/osteocyte apoptosis, but not the suppression of bone formation.  
Consistent with the musculoskeletal response of KO mice, pharmacologic inhibition of Pyk2 
with the kinase inhibitor PF-431396 (PF) prevented the loss of BMD induced by short-term (2 
weeks) treatment with GC (Figure 3A). In contrast, and similar to the genetic deletion of Pyk2, 
PF did not prevent the loss of lean body mass or the mass of individual muscles induced by GC 
(Figure 2A and B). PF-treated mice were also protected from GC-induced deterioration of 
femoral bone microarchitecture, specifically from trabecular and cortical thinning (Figure 3B-
C). PF prevented the reduction induced by GC in the cortical area fraction (Ct.Ar/Tt.Ar), which 
was mainly driven by the loss of cortical bone area (Ct.Ar) from the endosteal bone surface as no 
reductions in the cortical bone total cross-sectional area (Tt.Ar) were detected. PF also prevented 
the decreases in ultimate force, energy to ultimate load, and toughness induced by GC (Figure 
3D and Table 2). 
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The 2-week treatment with GC induced the expected increase in osteoblast and osteocyte 
apoptosis in cancellous and cortical bone in vehicle-treated mice, but not in PF-treated mice 
(Figure 3E). PF alone did not affect osteoblast/osteocyte apoptosis, but increased circulating 
P1NP and osteoblast number and surface compared to vehicle-treated mice (Figure 3F-G). 
However, all GC-treated mice exhibited similar reductions in P1NP, OCN, osteoblast number, 
and osteoblast surface regardless of PF administration when compared to respective placebo 
controls, demonstrating that GC affect osteoblast number and function independently of Pyk2 
activity (similar to genetic deletion of Pyk2 shown in Figure 1).   
Consistent with these in vivo effects of GC, addition of the synthetic GC dexamethasone 
decreased hydroxyapatite deposition to a similar extent in primary cultures of calvarial 
osteoblasts derived from WT or KO mice (Figure 3H); and decreased calcium deposition in the 
absence or presence of PF (Figure 3I). Further, mineral deposition was increased in cultures of 
KO-derived osteoblasts or osteoblasts treated with PF alone compared to the respective controls 
(Figure 3H-I), mimicking the increase in P1NP (Figure 3F) and in osteoblast number and 
surface (Figure 3G) exhibited by PF-treated mice. These findings are consistent with the 
increase in BFR/BS, MAR, MS/BS induced by PF in ovariectomized rats previously reported 
(27). These findings demonstrate that Pyk2 deletion/inhibition increases osteoblast activity under 
basal conditions but cannot overcome GC-induced decrease in matrix mineral production or bone 
formation.  
Loss of Pyk2 signaling by genetic or pharmacologic means protects from GC-induced bone 
resorption by decreasing activity of individual osteoclasts and promoting osteoclast detachment 
from bone.  
We next examine the effects of Pyk2 deletion/inhibition on GC-induced bone resorption. 
Circulating levels of the resorption marker CTX were not affected by genetic deletion of Pyk2 
(Figure 4A). However, KO mice exhibited increased circulating levels of TRAP5b, an index of 
osteoclast number (Figure 4B). As a consequence, KO mice exhibited lower CTX/TRAP5b 
ratio, which indicates decreased activity of individual osteoclasts (Figure 4C). Consistent with 
normal CTX levels in KO mice, the number of osteoclasts or the bone surface covered by 
osteoclasts quantified by histomorphometry was not different in KO compared to WT mice 
(Figure 4D, left and middle panels). However, KO mice exhibited approximately a 3-fold 
increase in the number of osteoclasts present in the bone marrow compared to WT, consistent 
with the increased TRAP5b in the circulation. Therefore, KO mice exhibited increased number 
of inactive osteoclasts detached from the bone surface explaining the mismatch between the low 
CTX/TRAP5b ratio.  
Both doses of GC induced the expected increase in CTX and TRAP5b in WT mice (Figure 
4A-B). However, GC did not affect CTX or further increase the already elevated circulating 
TRAP5b levels in KO mice. Moreover, GC did not change the CTX/TRAP5b ratio in either WT 
or KO mice (Figure 4C), suggesting that increased resorption induced by GC in WT mice is due 
to an increase in osteoclast number but not in the activity of individual osteoclasts. Indeed, GC 
increased osteoclast number in bone in both WT and KO mice, but GC increased osteoclast 
surface only in WT mice (Figure 4D, left and middle panels). Consistent with increased 
osteoclast number in the marrow (Figure 4D, right panel), mRNA expression of TRAPase as 
well as cathepsin K is increased in vertebral bone/bone marrow preparations from KO mice 
(Figure 4E). This finding demonstrates that osteoclasts in the marrow also express cathepsin K 
as the majority of osteoclasts in the KO mice are present in the marrow. Close examination of 
bone sections showed that osteoclasts were fully attached to bone in GC-treated WT mice, 
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(Figure 4F, top images). In contrast, osteoclasts were only partially attached in GC-treated KO 
mice (Figure 4F, bottom images). Cartoons and representative images of WT and KO 
osteoclasts are shown in Figure 4G. The difference in osteoclast attachment to bone surfaces 
explains the apparent discrepancy between osteoclast number and surface in response to GC in 
WT versus KO mice.  
The protection from bone loss induced by GC by genetic deletion of Pyk2 was reproduced by 
short-term blockade of Pyk2 kinase activity with the pharmacological inhibitor PF-431396 (PF). 
Two weeks of GC treatment increased CTX, TRAP5b, and osteoclast number and surface in 
vehicle-treated mice (Figure 4H and I). PF did not alter any of these parameters in placebo 
treated mice. However, PF inhibited the increase in CTX and osteoclast number/surface induced 
by GC. In contrast, PF did not inhibit the increase in TRAP5b induced by GC. Moreover, similar 
to genetic deletion of Pyk2, treatment with PF increased the number of osteoclasts in the 
marrow, which were further elevated in mice treated with both PF and GC. 
Decreased GC-induced resorption by genetic or pharmacologic inhibition of Pyk2 is due to 
osteoclast apoptosis, which overrides the prosurvival effects of GC on osteoclasts.  
The impaired attachment to bone of osteoclasts from KO or PF-treated mice was due to 
premature death by apoptosis, as evidenced by increased prevalence of apoptotic osteoclasts 
(TUNEL and TRAPase positive) on bone surfaces as well as in the bone marrow in bones from 
KO or from PF-treated mice compared to respective controls (Figure 5A-B). These findings 
strongly suggest that the reduction in osteoclast function by inhibition of Pyk2 signaling in vivo 
is due to detachment-induced apoptosis (i.e. anoikis).  
GC did not alter the increased osteoclast apoptosis in bone from either KO or PF-treated 
mice. However, mice treated with GC and the PF inhibitor exhibited a higher prevalence of 
apoptotic osteoclasts in the marrow compared to mice treated with PF alone. This effect 
paralleled the increased TRAP5b induced by GC (Figure 4H), suggesting that the increased 
osteoclasts generated by GC undergo premature apoptosis induced by PF and are unable to reach 
the bone surfaces, thus accumulating in the marrow.  
Increased apoptosis is an intrinsic feature of osteoclasts from KO mice, as it was evidenced 
in vitro in osteoclast precursors derived from KO mice cultured in the presence of RANKL and 
M-CSF (Figure 5C). Osteoclasts in these cultures exhibited abnormal morphology, impaired 
spreading, and absence of organized podosomes (Figure 5D), consistent with previous reports 
using immunofluoresecence microscopy to detect F-actin and tubulin and depicting morphologic 
defects of Pyk2 deficient osteoclasts in vitro (44). Moreover, KO osteoclast cultures exhibited a 
reduction in the total number of TRAPase positive cells with 3 or more nuclei (898 ± 238 vs 309 
± 249, WT vs KO respectively), suggesting that impaired attachment leads to premature 
apoptosis (i.e. anoikis). This phenomenon could explain the decreased activity of individual 
osteoclasts in vivo evidenced by a lower CTX/TRAP5b ratio (Figure 4C).  
Earlier findings showed that prolongation of the lifespan of preexisting osteoclasts explains 
part of the increase in bone resorption induced by GC (17;18). This anti-apoptotic effect of GC 
was readily demonstrated in cultures of osteoclasts derived from WT mice treated with the 
bisphosphonate (BP) alendronate (indicated by # in Figure 5C and images shown in Figure 5D). 
Thus, BP treatment increased apoptosis of TRAPase positive cells either with ≥3 nuclei or <3 
nuclei, which was prevented by dexamethasone by 60% and 46%, respectively. However, the 
survival effect of dexamethasone was absent in osteoclasts derived from KO mice. Further, 
whereas dexamethasone prevented BP-induced apoptosis in WT osteoclast cultures treated with 
vehicle by 51%, it was ineffective in cultures treated with the Pyk2 inhibitor PF (Figure 5E-F), 
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although PF addition did not significantly altered total number of TRAPase positive cells (1101 
± 280 vs 907 ± 144, veh vs PF, respectively). Taken together, these pieces of evidence 
demonstrate that prolongation of osteoclast lifespan by GC is negated in the absence of Pyk2 
expression/activity and, thus, the inherent osteoclast dysfunction and increased osteoclast 
apoptosis conferred by lack of Pyk2 overrides GC-induced resorption.  
Discussion  
We identified in the current studies the Pyk2/anoikis signaling pathway as a new therapeutic 
target that opposes GC effects on bone cells. Pyk2 activation is required for GC to induce 
apoptosis of osteoblasts and osteocytes and to prolong the lifespan of osteoclasts, leading to 
increased resorption. Either genetic deletion or short-term pharmacologic inhibition of Pyk2 
overrides GC regulation of bone cell anoikis, maintaining osteoblast/osteocyte viability while 
shortening osteoclast lifespan. Remarkably, Pyk2 inhibition prevents bone loss primarily by 
inhibiting resorption and interfering with osteoclast survival induced by GC, as bone formation is 
still suppressed even when osteoblast apoptosis induced by GC is prevented by Pyk2 inhibition. 
Importantly, inhibiting Pyk2 signaling bypasses the negative effects of the current standard of 
care, thus preserving bone renewal rate and the biomechanical material properties of bone. We 
conclude that targeting the Pyk2/anoikis pathway represents a novel mechanistic approach to 
maintain skeletal integrity with GC excess (Figure 6). 
Our studies reveal that the Pyk2 kinase is at the core of the mechanism underlying the 
opposing regulation of apoptosis by GC depending on the bone cell lineage, a hallmark of GC 
action. Whereas Pyk2 phosphorylation induced by GC promotes apoptosis of osteoblasts and 
osteocytes, it stimulates podosome formation and induces attachment of osteoclasts to bone 
surfaces, prolonging osteoclast lifespan. Consequently, genetic absence of Pyk2 or treatment 
with a Pyk2 inhibitor prevented GC effects on bone cell anoikis maintaining osteoblast/osteocyte 
viability and at the same time promoting osteoclast apoptosis.  
A remarkable feature of the Pyk2/anoikis pathway is that its pharmacologic inhibition rapidly 
inhibits bone resorption stimulated by GC by inducing osteoclast detachment from bone and 
apoptosis of osteoclasts, which accumulate in the marrow. This mechanism could potentially be 
exploited to block bone loss in other pathological conditions in which osteoclast production is 
exaggerated. In particular, inhibitors of Pyk2/anoikis signaling could also potentially block the 
bone loss associated with aging, which is another leading cause of osteoporosis world-wide. GC 
activity is regulated by two isoforms of 11β-hydroxysteroid dehydrogenase (11β-HSD): 11β-
HSD1 that converts inactive (cortisone) to active (cortisol) metabolites and 11β-HSD2 that 
catalyzes the opposite reaction (45). The level of expression of 11β-HSD1 predicts the severity 
of the skeletal response to GC action (46) and also increases with age (47). Thus, exaggerated 
endogenous GC activity likely contributes to the mechanism underlying age-related bone loss, 
and interventions that prevent iatrogenic GC-induced bone disease could also ameliorate the 
skeletal fragility due to aging.  
Unlike bisphosphonates and denosumab (RANKL antibody), also used to manage GC-
induced osteoporosis (9-12;48), targeting the Pyk2/anoikis pathway decreased bone resorption to 
placebo levels without severely reducing bone turnover, and did not further suppress bone 
formation below the already low rate induced by GC. Thus, inhibition of the Pyk2/anoikis 
pathway represents an alternative approach to effectively reduce GC-induced resorption, while 
circumventing the side-effects associated with potent anti-resorptive agents.  
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Apoptosis of osteoblasts induced by GC is prevented by Pyk2 inhibition. However, bone 
formation is still suppressed in the KO mice or in mice treated with the Pyk2 inhibitor. These 
findings suggest minimal, if any, contribution of apoptosis to osteoblast function in the frame of 
GC excess. This outcome is not surprising, considering the pleiotropic effects of the hormones, 
which affect osteoblast function by several mechanisms. Indeed, in mice with Pyk2 genetic 
deletion, GC still inhibited the synthetic activity of osteoblasts as evidenced by the reduction in 
osteocalcin, collagen 1a1, and alkaline phosphatase expression. These findings demonstrate that 
Pyk2 inhibition specifically interferes with the regulation of osteoblast anoikis by GC, whereas 
GC inhibition of bone formation and mineral matrix production in osteoblasts occurs 
independently of Pyk2. Future investigations are required to examine the efficacy of Pyk2 
inhibition in long term experiments in which bone loss induced by GC is primarily driven by the 
reduction in bone formation induced by the hormones.   
Maintenance of osteocyte viability with Pyk2 inhibition could contribute to preservation of 
bone strength in our studies, as previous reports demonstrated that prevention of osteocyte 
apoptosis by genetic means preserves at least part of bone strength even when GC induce loss of 
bone mineral (15). Future studies are warranted to examine whether long term inhibition of Pyk2 
activity prevents the development of osteonecrosis, a process that has been linked to GC-induced 
osteocyte apoptosis (49).  
Because of bone and muscle act as a mechanical unit, it could be expected that changes in 
one tissue might impact the other. However, in contrast to the observed bone protection, KO or 
PF-treated mice still exhibited muscle wasting induced by GC. These findings show a lack of 
crosstalk between these two tissues in the context of GC excess and also demonstrate that the 
effects of the GC on skeletal muscle are independent of Pyk2 expression or activity. One 
mechanism by which bone might influence muscle is through growth factors stored in the bone 
matrix. In particular, TGF-β released into the circulation by the process of bone resorption has 
been implicated in the oxidation and nitrosylation of the ryanodine receptor and calcium release 
channel (RyR1) in skeletal muscle leading to muscle weakness in cancer (50). Our findings in 
which Pyk2 inhibition effectively blocks resorption but does not alter muscle atrophy argue 
against this mechanism in the context of GC excess. Similarly, blocking GC-induced resorption 
by genetic deletion of Sost/sclerostin does not protect muscle (25). Taken together, this evidence 
highlights the need for therapeutic interventions that simultaneously interfere with the damaging 
actions of GC in both bone and muscle.  
In conclusion, targeting the Pyk2/anoikis pathway represents a novel mechanistic approach to 
preserve skeletal integrity in glucocorticoid excess, devoid of undesirable skeletal complications. 
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Figure 1. Life-long genetic deletion of Pyk2 protects from GC-induced loss of bone mass 
and strength, and osteoblast/osteocyte apoptosis. (A) BMD for WT or KO mice treated with 
placebo, 1.4 mg/kg/d prednisolone (GC1), or 2.1 mg/kg/d prednisolone (GC2) for 28 days, 
measured by DXA. WT, N=10/10/9, placebo/GC1/GC2; KO N=10/9/7, placebo/GC1/GC2. (B-
C) Bone volume fraction of bone volume/tissue volume (BV/TV), trabecular thickness (Tb.Th), 
number (Tb.N), and separation (Tb.Sp) of WT or KO lumbar vertebrae L6 are shown. WT, 
N=10/10/9, placebo/GC1/GC2; KO N=10/9/7, placebo/GC1/GC2. (D) Biomechanical properties 
were measured in vertebral bone (L6) by axial compression testing; WT, N=10/10/9, 
placebo/GC1/GC2; KO N=10/9/7, placebo/GC1/GC2. (E) Apoptosis of osteoblasts (Ob) and 
osteocytes (Ot) was quantified in cancellous and cortical bone in longitudinal sections of lumbar 
vertebrae (L1-L3) of WT or KO mice stained for TUNEL. WT, N=4/3/4, placebo/GC1/GC2; KO 
N=4/3/3, placebo/GC1/GC2. (F-G) P1NP, WT, N=10/10/10, placebo/GC1/GC2; KO N=8/10/10, 
placebo/GC1/GC2, and OCN, WT, N=7/7/6, placebo/GC1/GC2; KO N=7/6/6, 
placebo/GC1/GC2, were measured in blood samples collected 2 and 4 weeks after pellet 
implantation for WT or KO mice. (H) Mineralizing bone surface per bone surface (MS/BS), 
mineral apposition rate (MAR), and bone formation rate per bone surface (BFR/BS) were 
quantified in longitudinal sections of lumbar vertebra (L1-L3). WT, N=5/4/4, placebo/GC1/GC2; 
KO N=5/4/4, placebo/GC1/GC2. (I) Expression of indicated genes in L4 bones is shown, WT, 
N=8/8/8, placebo/GC1/GC2; KO N=8/8/8, placebo/GC1/GC2. Bars represent means ± SD. 
*p<0.05 vs corresponding placebo-treated mice and #p<0.05 vs placebo-treated WT mice, by 
two-way ANOVA, Tukey post-hoc test.   
Figure 2. Pyk2 deficiency or inhibition does not prevent glucocorticoid induced muscle 
wasting. Lean body mass (A) and mass of isolated muscles normalized by body weight (B) are 
shown. WT, N=10/10/9, placebo/GC1/GC2; KO N=10/9/7, placebo/GC1/GC2; veh, N=9/9, 
placebo/GC2; PF N=10/6, placebo/GC2. *p<0.05 vs corresponding placebo-treated mice and 
#p<0.05 vs corresponding GC-treated WT mice by two-way ANOVA, Tukey post-hoc test. 
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Figure 3. Short-term pharmacologic Pyk2 inhibition prevents GC-induced bone loss, 
fragility, and osteoblast/osteocyte apoptosis. (A) BMD for vehicle (veh) or PF-431396 (PF) 
treated C57BL/6 mice implanted with placebo or 2.1 mg/kg/d prednisolone (GC2) for 14 days, 
measured by DXA. veh, N=9/9, placebo/GC2; PF N=10/6, placebo/GC2. (B) BV/TV, Tb.Th, 
Tb.N, and Tb.Sp of the distal femur of veh or PF-treated mice measured by micro-CT. veh, 
N=9/9, placebo/GC2; PF N=10/6, placebo/GC2. (C) Cortical area fraction (Ct.Ar/Tt.Ar), cortical 
bone area (Ct.Ar), total cross-sectional area (Tt.Ar), and cortical thickness (Ct.Th) of veh or PF-
treated femoral midshafts are shown. veh, N=9/9, placebo/GC2; PF N=10/6, placebo/GC2. (D) 
Biomechanical properties were measured in the femoral mid-diaphysis by three-point bending. 
veh, N=9/9, placebo/GC2; PF N=10/6, placebo/GC2. (E) Osteoblasts (Ob) and osteocytes (Ot) 
apoptosis was quantified in cancellous and cortical bone in TUNEL stained longitudinal lumbar 
vertebrae (L1-L3) sections of veh or PF-treated mice. veh, N=5/5, placebo/GC2; PF N=5/3, 
placebo/GC2 N=3-5. (F) P1NP, veh, N=9/9, placebo/GC2; PF N=10/6, placebo/GC2, and OCN, 
veh, N=7/7, placebo/GC2; PF N=7/6, placebo/GC2, were measured in veh or PF-treated mice. 
(G) Osteoblast number (Ob.N/BS) and surface (Ob.S/BS) normalized to bone surface were 
measured in von Kossa/McNeal stained longitudinal distal femur sections. veh, N=3/3, 
placebo/GC2; PF N=3/4, placebo/GC2. (H) Quantification of mineralization in cultures of 
calvaria-derived primary osteoblastic cells from WT or KO mice treated with vehicle (veh) or 
dexamethasone (dex) and stained using the OsteoImage Mineralization Assay Kit. Scale bars: 
400 µm. WT, N=8/7, veh/dex; KO N=8/8, veh/dex. (I) Mineralization quantification of calvaria-
derived primary osteoblastic cell cultures from C57BL/6 mice treated with or without PF-431396 
with veh or dex for 10 days stained using Alizarin Red S (405nm absorbance). veh, N=4/4, 
veh/dex; PF N=4/4, veh/dex, measured in triplicate. Bars represent means ± SD. (A-G) *p<0.05 
vs corresponding placebo-treated mice and #p<0.05 vs placebo-treated WT mice by two-way 
ANOVA, Tukey post-hoc test. (H-I) *p<0.05 vs corresponding vehicle-treated cells and #p<0.05 
vs vehicle-treated cells without GC by two-way ANOVA, Tukey post-hoc test. 
Figure 4. Loss of Pyk2 signaling by genetic or pharmacologic means protects from GC-
induced bone resorption by decreasing activity of individual osteoclasts and promoting 
osteoclast detachment from bone. (A-C and H) CTX, WT, N=7/7/7, placebo/GC1/GC2; KO 
N=7/6/6, placebo/GC1/GC2, TRAP5b, WT, N=7/6/6, placebo/GC1/GC2; KO N=7/6/6, 
placebo/GC1/GC2, CTX/TRAP5b, WT, N=7/5/6, placebo/GC1/GC2; KO N=7/6/6, 
placebo/GC1/GC2, were measured in blood collected 4 weeks after pellet implantation for WT 
or KO mice and CTX, veh, N=9/9, placebo/GC2; PF N=10/6, placebo/GC2, and TRAP5b, veh, 
N=9/9, placebo/GC2; PF N=10/6, placebo/GC2, were measured after 2 weeks for veh and PF-
treated mice. (D and I) Osteoclast number (N.Oc/BS) and surface (Oc.S/BS) normalized to bone 
surface and marrow osteoclast number normalized to total marrow cavity area were determined 
in longitudinal sections of lumbar vertebra (L1-L3) for WT, N=6/6/6, placebo/GC1/GC2; KO 
N=6/6/6, placebo/GC1/GC2 mice, or of longitudinal distal femur sections, veh, N=6/8, 
placebo/GC2; PF N=8/5, placebo/GC2, for veh or PF-treated mice. (E) Expression of indicated 
genes in L4 bones is shown, WT, N=8/8/8, placebo/GC1/GC2; KO N=8/8/8, placebo/GC1/GC2. 
(F) Representative microscopy images of osteoclasts on cancellous bone surface or in the 
marrow of lumbar vertebra (L2) stained for TRAPase. Arrows point to osteoclasts fully attached 
to bone on top images from WT mice and osteoclasts partially attached on bottom images from 
KO mice. Scale bars: 25 µm. (G) Cartoons and representative high magnification images of WT 
and KO osteoclasts. Bars represent means ± SD. (A-E)*p<0.05 vs corresponding placebo-treated 
mice and #p<0.05 vs placebo-treated WT mice, by two-way ANOVA, Tukey post-hoc test. (H-I) 
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*p<0.05 vs corresponding vehicle-treated mice and #p<0.05 vs placebo and vehicle-treated mice 
by two-way ANOVA, Tukey post-hoc test.  
Figure 5. Decreased GC-induced resorption by genetic or pharmacologic inhibition of Pyk2 
is due to osteoclast apoptosis, which overrides the prosurvival effects of GC on osteoclasts. 
(A-B) Apoptotic osteoclasts on bone (left graphs) and in the marrow (right graphs) were 
quantified in double stained TRAPase and TUNEL longitudinal sections of the distal femur. WT, 
N=6/6/6, placebo/GC1/GC2; KO N=6/6/6, placebo/GC1/GC2 or veh, N=5/6, placebo/GC2; PF 
N=6/6, placebo/GC2. Representative microscopy images of TUNEL negative osteoclasts fully 
attached to bone in WT mice and TUNEL positive osteoclasts partially attached to bone in KO 
mice are shown on the right of (A). Scale bars: 20 µm. (C-F) Apoptosis of differentiated primary 
osteoclasts was quantified by evaluating loss of cell membrane integrity, nuclear condensation, 
and nuclear fragmentation.  Osteoclasts derived from KO and WT mice (C and D) or from 
C57BL/6 mice treated with or without PF (E and F), were treated in vitro with alendronate, 
dexamethasone (dex), or respective vehicles (veh), for 24 hours. TRAPase and hematoxylin 
staining were subsequently performed. Green star and arrow symbols indicate alive and 
apoptotic osteoclasts, respectively, in D and F. Scale bars: 20 µm. N=6. Bars represent means ± 
SD. (A-B) *p<0.05 vs corresponding placebo-treated mice and #p<0.05 vs placebo-treated mice, 
by two-way ANOVA, Tukey post-hoc test. (C and E) *p<0.05 vs corresponding vehicle-treated 
cells and #p<0.05 vs alendronate treated cells from WT or C57BL/6 mice by three-way 
ANOVA, Tukey post-hoc test. 
Figure 6. Inhibition of the Pyk2/anoikis pathway represents a novel mechanistic approach 
to preserve skeletal integrity with GC excess. Activation of proline-rich tyrosine kinase 2 
(Pyk2) is required for the opposing GC regulation of bone cell anoikis, depending on bone cell 
lineage, with anti-apoptotic effects for osteoclasts but pro-apoptotic effects for 
osteoblasts/osteocytes. Inhibiting Pyk2 activation prevents GC-induced bone loss and fragility by 
stimulating osteoclasts anoikis and preventing osteoblasts/osteocytes anoikis, without further 
suppressing bone renewal rate or altering biomechanical material properties. Targeting the 
Pyk2/anoikis pathway is a novel mechanistic approach to preserve skeletal integrity with GC, 
without undesirable skeletal complications. 
Table 1. Genetic deletion of Pyk2 protects from GC-induced loss of bone strength 
L6 axial compression 
(cancellous bone) WT placebo WT GC1 WT GC2 KO placebo KO GC1 KO GC2 
Structural (or extrinsic) mechanical properties 
Energy to Ultimate Force, 
mJ 4.1 ±0.8 *2.1 ±1.5 *2.0 ±1.4 #6.3 ±1.8 6.8 ±1.2 5.9 ±1.4 
Ultimate Force, N 16.8 ±2.7 11.8 ±4.1 *9.5 ±3.3 #24.8 ±3.3 22.7 ±6.3 25.2 ±6.3 
Stiffness, N/mm 71.7 ±14.9 83.0 ±19.4 61.0 ±23.1 #105.6 ±21.0 113.1 ±30.0 103.2 ±27.5 
Material (or intrinsic) mechanical properties 
Toughness, mJ/mm3 14.9 ±3.7 *9.1 ±4.7 *6.2 ±4.7 15.5 ±5.6 14.0 ±1.3 13.5 ±1.5 
Ultimate Stress, MPa 1.8 ±0.4 1.3 ±0.3 1.4 ±0.5 1.8 ±0.3 1.6 ±0.6 1.7 ±0.4 
Young’s modulus, MPa 728.7 ±276.9 717.8 ±187.3 566.5 ±276.1 739.8 ±285.6 763.3 ±282.8 712.8 ±222.8 
Biomechanical properties were measured in vertebral bone (L6) by axial compression testing. WT, N=10/10/9, 
placebo/GC1/GC2; KO N=10/9/7, placebo/GC1/GC2. *p<0.05 vs corresponding placebo-treated mice and #p<0.05 
vs placebo-treated WT mice, by two-way ANOVA, Tukey post-hoc test.  
Table 2. Pyk2 pharmacologic inhibition prevents from GC-induced bone fragility 
3 point bending (cortical bone) Veh placebo Veh GC2 PF-431396 placebo PF-431396 GC2 
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Structural (or extrinsic) mechanical properties 
Energy to Ultimate Force, mJ 2.9 ±0.4 *2.0 ±0.5 2.8 ±0.8 2.5 ±0.7 
Ultimate Force, N 12.6 ±0.9 *10.9 ±0.6 12.5 ±1.4 11.7 ±1.9 
Stiffness, N/mm 59.0 ±4.9 54.1 ±6.0 57.0 ±5.6 56.9 ±7.6 
Material (or intrinsic) mechanical properties 
Toughness, mJ/mm3 11.8 ±1.9 *8.4 ±1.7 11.4 ±1.5 11.6 ±1.4 
Ultimate Stress, MPa 174.9 ±12.9 168.1 ±12.5 170.7 ±15.8 174.5 ±18.7 
Young’s modulus, MPa 2927.6 ±253.7 2892.7 ±397.5 2778.1 ±365.0 2966.2 ±112.5 
 
Biomechanical properties were measured in the femoral mid-diaphysis by three-point bending; veh, N=9/9, 
placebo/GC2; PF N=10/6, placebo/GC2. *p<0.05 vs corresponding vehicle-treated mice and #p<0.05 vs placebo and 
vehicle-treated WT mice by two-way ANOVA, Tukey post-hoc test. 
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